GRACEcast Cancer 101 Audio

By cancerGRACE - H. Jack West, MDMedicine Education

GRACEcast Cancer 101 Audio episodes

March 11, 2013 Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center discusses the current role of interleukin-2 (IL-2) in the context of many other treatment alternatives for metastatic renal cell carcinoma.
3 min
March 11, 2013 Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.
2 min
March 10, 2013 What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?
Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for.
2 min
March 07, 2013 Dr. Monty Pal: Reviewing Bladder Cancer Stages, the Role of Surgery, and the Potential Role of Chemotherapy for Localized Bladder Cancer
Dr. Sumanta (Monty) Pal, City of Hope Cancer Center, summarizes basic stages of bladder cancer, value of surgery, and survival benefit of neoadjuvant (pre-operative) chemotherapy for higher risk muscle-invasive bladder cancer.
4 min
March 07, 2013 Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
Dr. Sarah Goldberg notes that while maintenance therapy after first line treatment of advanced NSCLC is always worthy of a discussion, many patients need and benefit from a break from treatment to recover before pursuing additional therapy.
2 min
March 07, 2013 Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?
Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.
3 min
March 07, 2013 Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?
Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.
3 min
March 05, 2013 Dr. Larry Einhorn: Will Costs of Care Limit Our Ability to Deliver Cancer Treatments?
Dr. Larry Einhorn, Indiana University, expresses his concerns about the cost of developing cancer drugs and the challenge of paying for extremely expensive cancer treatments that are given in anticipation of modest clinical benefits.
3 min
March 05, 2013 Dr. Larry Einhorn: How Can We Replicate the High Cure Rates We've Achieved for Testicular Cancer in a Wide Range of Cancers?
Dr. Larry Einhorn, Indiana University, explains why some cancers such as testicular cancer can have such a high cure rate while most others are far more challenging to cure with our current systemic therapies, offering an optimistic view of the future.
3 min
March 05, 2013 Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, including surgery and the role of any additional post-surgical treatment.
3 min

About GRACEcast Cancer 101 Audio

From the publisher's feed

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to…